The effect of targeted high intensity interval training (HIIT) during cardiotoxic cancer treatment on cardiovascular health – a pilot study

Phase 3

Recruiting

• Conditions: Patients with initial diagnosis of cancer (breast cancer) prior to outpatient anthracycline therapy; C50; Malignant neoplasm of breast

• Registration Number: DRKS00030884
• Lead Sponsor: niklinik Köln

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-12
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

Patients (= 18 years) with initial diagnosis of cancer (breast cancer).
- Indication for anthracycline therapy
- Prior to initiation of medical therapy (max. 2 weeks after diagnosis).
- Life expectancy =18 months
- Written and valid informed consent from the patient.

Exclusion Criteria

- Contraindications to exercise therapy interventions and all disease situations that do not allow exercise, in particular:
- previous myocardial infarction or CABG
- angina pectoris
- EF < 50%
- previous cardiotoxicity / or previous potential cardiotoxic therapy
- Age > 80 years
- BMI > 30 or > 150 kg body weight

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
cardiovascular health<br>- echocardiography (LVEF, Strain), ECG (QT-Time), endothelial measurement (retina, upper arm), Biomarker (Troponin-T, NT-pro-BNP)

Secondary Outcome Measures

Name	Time	Method
feasibility<br>- implementation (organisation, time), aherence, practicability, content<br>effective trends<br>- movement behavior, cardiorespiratory fitness, cardiovascular riskprofile (SCORE-riskdiagram)